Studying right heart failure linked to heart failure and pulmonary hypertension
Observes right ventricle muscle function in adults with reduced-ejection heart failure and pulmonary hypertension.
Plain-language title generated from the registry record
Registry title: Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure
Key facts
- Where
- Baltimore, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Source: NCT06299436, who can take part
Where in United States
- Johns Hopkins HospitalBaltimore, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Johns Hopkins University
- Trial code
- NCT06299436
- Record updated
- 12 January 2026
- Original description
Right ventricular (RV) failure is recognized to worsen patient outcomes in the setting of heart failure with reduced ejection fraction (HFrEF)-related pulmonary hypertension (PH), yet the investigators fall short in trying to identify and treat it. The current proposal will (1) determine the best clinical indicators of intrinsic RV myocyte contractile failure in humans with HFrEF-PH, (2) clarify underlying mechanisms, and (3) test novel treatments on RV myocytes. The long-term goal of this proposal will be to better identify and treat RV failure in humans suffering from HFrEF-PH.Read full original descriptionShow less
Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure
Right ventricular (RV) failure is recognized to worsen patient outcomes in the setting of heart failure with reduced ejection fraction (HFrEF)-related pulmonary hypertension (PH), yet the investigators fall short in trying to identify and treat it. The current proposal will (1) determine the best clinical indicators of intrinsic RV myocyte contractile failure in humans with HFrEF-PH, (2) clarify underlying mechanisms, and (3) test novel treatments on RV myocytes. The long-term goal of this proposal will be to better identify and treat RV failure in humans suffering from HFrEF-PH.
Inclusion: Adult patients aged between 18 and 90 years of age; Diagnosed with heart failure with reduced ejection fraction (LV ejection fraction ≤ 40-50%); Can safely hold direct oral anticoagulant (DOAC) vitamin K antagonist (VKA) for 48 hours prior to the procedure.
Exclusion: Acute hospitalization or decompensation within 2 weeks prior to study date; Participation in a study involving an investigational drug within 4 weeks prior to study date; Point of care International Normalized Ratio (INR) > 1.5; Unable to interrupt VKA anticoagulation; Pregnant patients; Inability to lie flat in the supine position; Symptomatic hemodynamic instability at rest or during the procedure.